Researchers report early findings suggesting an experimental Alzheimer’s drug could slow cognitive decline in the early stages by targeting tau, a brain protein. In a result discussed by multiple outlets citing AP reporting, the drug is designed to lower tau levels, an approach described as different from current medicines. Current Alzheimer’s therapies such as lecanemab and donanemab work by targeting amyloid protein buildup, and they have been associated with only modest slowing of cognitive decline. The new study involves roughly 400 participants and evaluates Biogen’s diranersen. Reporting indicates the treatment reduces tau and may have additional effects on cognition beyond lowering the protein, with signs of slowed cognitive decline appearing in a small subset of participants. The outlets also note that earlier efforts to develop drugs targeting tau had largely failed, making this report notable as a potential alternative pathway. The findings are presented as preliminary and are part of ongoing research efforts to identify new ways to slow the disease, particularly early on.